• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

多发性硬化症中的弗雷明汉心血管风险评分。

The Framingham cardiovascular risk score in multiple sclerosis.

机构信息

Department of Neuroscience, Reproductive Science and Odontostomatology, Federico II University, Naples, Italy.

Department of Public Health, Federico II University, Naples, Italy.

出版信息

Eur J Neurol. 2015 Aug;22(8):1176-83. doi: 10.1111/ene.12720. Epub 2015 Apr 27.

DOI:10.1111/ene.12720
PMID:25912468
Abstract

BACKGROUND AND PURPOSE

Cardiovascular risk factors can increase the risk of multiple sclerosis (MS) and modify its course. However, such factors possibly interact, determining a global cardiovascular risk. Our aim was to compare the global cardiovascular risk of subjects with and without MS with the simplified 10-year Framingham General Cardiovascular Disease Risk Score (FR) and to evaluate its importance on MS-related outcomes.

METHODS

Age, gender, smoking status, body mass index, systolic blood pressure, type II diabetes and use of antihypertensive medications were recorded in subjects with and without MS to estimate the FR, an individualized percentage risk score estimating the 10-year likelihood of cardiovascular events.

RESULTS

In total, 265 MS subjects were identified with 530 matched controls. A t test showed similar FR in cases and controls (P = 0.212). Secondary progressive MS presented significantly higher FR compared to relapsing-remitting MS (P < 0.001). Linear regression analysis showed a direct relationship between FR and Expanded Disability Status Scale (P < 0.001) and MS Severity Scale (P < 0.001).

CONCLUSION

The FR, evaluating the global cardiovascular health by the interaction amongst different risk factors, relates to MS disability, severity and course.

摘要

背景与目的

心血管危险因素会增加多发性硬化症(MS)的风险,并改变其病程。然而,这些因素可能相互作用,从而确定整体心血管风险。我们的目的是比较有和无 MS 的患者的整体心血管风险与简化的 10 年 Framingham 一般心血管疾病风险评分(FR),并评估其对 MS 相关结局的重要性。

方法

记录有和无 MS 的患者的年龄、性别、吸烟状况、体重指数、收缩压、2 型糖尿病和使用降压药物的情况,以估计 FR,这是一种个体化的百分比风险评分,用于估计 10 年内发生心血管事件的可能性。

结果

共确定了 265 例 MS 患者,有 530 例匹配对照。t 检验显示病例和对照组的 FR 相似(P=0.212)。继发进展型 MS 的 FR 明显高于复发缓解型 MS(P<0.001)。线性回归分析显示 FR 与扩展残疾状况量表(EDSS)(P<0.001)和 MS 严重程度量表(MSSS)(P<0.001)呈直接关系。

结论

FR 通过不同危险因素的相互作用评估整体心血管健康,与 MS 的残疾、严重程度和病程相关。

相似文献

1
The Framingham cardiovascular risk score in multiple sclerosis.多发性硬化症中的弗雷明汉心血管风险评分。
Eur J Neurol. 2015 Aug;22(8):1176-83. doi: 10.1111/ene.12720. Epub 2015 Apr 27.
2
Multiple sclerosis clinical course and cardiovascular disease risk - Swedish cohort study.多发性硬化症临床病程与心血管疾病风险——瑞典队列研究
Eur J Neurol. 2014 Nov;21(11):1353-e88. doi: 10.1111/ene.12518. Epub 2014 Jul 17.
3
Risk of secondary progressive multiple sclerosis: A longitudinal study.继发进展型多发性硬化症的风险:一项纵向研究。
Mult Scler. 2020 Jan;26(1):79-90. doi: 10.1177/1352458519868990. Epub 2019 Aug 9.
4
Long-term influence of combined oral contraceptive use on the clinical course of relapsing-remitting multiple sclerosis.长期口服避孕药的使用对复发性缓解型多发性硬化临床病程的影响。
Fertil Steril. 2014 Jul;102(1):116-22. doi: 10.1016/j.fertnstert.2014.03.054. Epub 2014 Apr 29.
5
Is malnutrition a problem for multiple sclerosis patients?营养不良是多发性硬化症患者面临的一个问题吗?
J Clin Neurosci. 2014 Sep;21(9):1603-5. doi: 10.1016/j.jocn.2013.12.024. Epub 2014 Jun 3.
6
Epilepsy in multiple sclerosis: A nationwide population-based register study.多发性硬化症中的癫痫:一项基于全国人口登记的研究。
Neurology. 2017 Dec 12;89(24):2462-2468. doi: 10.1212/WNL.0000000000004740. Epub 2017 Nov 8.
7
Cigarette smoking and the risk of multiple sclerosis: a sibling case-control study in Isfahan, Iran.吸烟与多发性硬化症的风险:伊朗伊斯法罕的一项兄妹病例对照研究。
Neuroepidemiology. 2011;37(3-4):238-42. doi: 10.1159/000332765. Epub 2011 Dec 7.
8
ADC measurements in various patterns of multiple sclerosis lesions.多发性硬化症病变不同模式下的表观扩散系数测量
J Med Assoc Thai. 2006 Feb;89(2):196-204.
9
Vitamin D is associated with degree of disability in patients with fully ambulatory relapsing-remitting multiple sclerosis.维生素D与完全可走动的复发缓解型多发性硬化症患者的残疾程度相关。
Eur J Neurol. 2015 Mar;22(3):564-9. doi: 10.1111/ene.12617. Epub 2014 Dec 20.
10
T2 lesions and rate of progression of disability in multiple sclerosis.多发性硬化症中的 T2 病变和残疾进展率。
Eur J Neurol. 2010 Dec;17(12):1471-5. doi: 10.1111/j.1468-1331.2010.03093.x.

引用本文的文献

1
Unmasking the Silent Threat: Prevalence of Cardiovascular Risk Factors in MS Patients in Bucharest, Romania.揭开无声威胁:罗马尼亚布加勒斯特多发性硬化症患者心血管危险因素的患病率
J Clin Med. 2025 Mar 15;14(6):2001. doi: 10.3390/jcm14062001.
2
Trajectories and management of vascular risk following the diagnosis of multiple sclerosis: A population-based matched cohort study between 1987 and 2018 in England.血管风险在多发性硬化症诊断后的轨迹和管理:1987 年至 2018 年在英格兰进行的基于人群的匹配队列研究。
Mult Scler. 2024 Nov;30(13):1653-1663. doi: 10.1177/13524585241287388. Epub 2024 Oct 17.
3
Comorbidity and Disease Activity in Multiple Sclerosis.
多发性硬化症中的共病与疾病活动度
JAMA Neurol. 2024 Sep 18;81(11):1170-7. doi: 10.1001/jamaneurol.2024.2920.
4
An Association of Framingham Risk Score with Patient Determined Disease Steps in a Cohort of Relapsing-Remitting Multiple Sclerosis Patients: An Italian Real-World Monocentric Experience.在一组复发缓解型多发性硬化症患者中,弗雷明汉风险评分与患者自我确定的疾病阶段的关联:一项意大利真实世界单中心经验。
Curr Neuropharmacol. 2025;23(3):310-316. doi: 10.2174/1570159X22666240815120018.
5
Clinical Characteristics and Long-Term Outcomes of Late-Onset Multiple Sclerosis: A Swedish Nationwide Study.迟发性多发性硬化的临床特征和长期预后:一项瑞典全国性研究。
Neurology. 2024 Mar 26;102(6):e208051. doi: 10.1212/WNL.0000000000208051. Epub 2024 Feb 23.
6
Modelling Disease Progression of Multiple Sclerosis in a South Wales Cohort.在南威尔士队列中对多发性硬化症的疾病进展进行建模。
Neuroepidemiology. 2024;58(3):218-226. doi: 10.1159/000536427. Epub 2024 Feb 20.
7
The Prevalence of Diabetes Mellitus Type II (DMII) in the Multiple Sclerosis Population: A Systematic Review and Meta-Analysis.多发性硬化症人群中2型糖尿病(DMII)的患病率:一项系统评价和荟萃分析。
J Clin Med. 2023 Jul 27;12(15):4948. doi: 10.3390/jcm12154948.
8
Management of vascular risk in people with multiple sclerosis at the time of diagnosis in England: A population-based study.在英国,对多发性硬化症患者进行诊断时的血管风险管理:一项基于人群的研究。
Mult Scler. 2023 May;29(6):671-679. doi: 10.1177/13524585231164296. Epub 2023 Apr 7.
9
Using personalized prognosis in the treatment of relapsing multiple sclerosis: A practical guide.在复发型多发性硬化症的治疗中应用个体化预后预测:实用指南。
Front Immunol. 2022 Sep 27;13:991291. doi: 10.3389/fimmu.2022.991291. eCollection 2022.
10
The Molecular Aspects of Disturbed Platelet Activation through ADP/P2Y Pathway in Multiple Sclerosis.多发性硬化症中 ADP/P2Y 通路异常血小板激活的分子机制。
Int J Mol Sci. 2021 Jun 18;22(12):6572. doi: 10.3390/ijms22126572.